

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
8 June 2006 (08.06.2006)

PCT

(10) International Publication Number
WO 2006/058724 A1

(51) International Patent Classification:

C07D 495/14 (2006.01) A61K 31/519 (2006.01)

C07D 495/22 (2006.01) A61P 11/06 (2006.01)

(21) International Application Number:

PCT/EP2005/012774

(22) International Filing Date:

30 November 2005 (30.11.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

P200402876 30 November 2004 (30.11.2004) ES

(71) Applicant (for all designated States except US): **ALMIRALL PRODESFARMA, S.A.** [ES/ES]; Ronda del General Mitre 151, E-08022 Barcelona (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PAGES SANTACANA, Lluís, Miquel** [ES/ES]; C/Calabria 242, 1° 3a., E-08029 Barcelona (ES). **TALTAVULL MOLL, Joan** [ES/ES]; C/ Joan Güell, 134, 2° 3a, E-08028 Barcelona (ES).(74) Agent: **R C SRINIVASAN**; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW PYRIDOTHIEOPYRIMIDINE DERIVATIVES



(57) Abstract: Use of a pyridothienopyrimidine derivative of formula (I), and the pharmaceutically acceptable salts and N-oxides thereof, wherein G^1 represents a group selected from $-CR^6R^7-$ or $-NR^6$ being R^6 and R^7 independently selected from hydrogen atoms and C_{1-4} alkyl groups m and n are integers selected from 0 or 1 R^1 and R^2 are independently selected from hydrogen atoms and C_{1-4} alkyl groups R^3 represents a group selected from alkyl, amino, monoalkylamino, dialkylamino, aryl, heteroaryl and saturated N-containing heterocyclyl groups bound through the nitrogen atom to the pyridine ring, all of them being optionally substituted by one or more substituents selected from the group consisting of halogen atoms and alkyl, alkoxyalkyl, arylalkyl, R^8OCO- , alkoxy, R^8R^9N-CO- , $-CN$, $-CF_3$, $-NR^8R^9$, $-SR^8$ and $-SO_2NH_2$ groups wherein R^8 and R^9

are independently selected from hydrogen atoms and C_{1-4} alkyl groups R^4 and R^5 are independently selected from the group consisting of hydrogen atoms alkyl groups and groups of formula (II), wherein p and q are integers selected from 1, 2 and 3; A is either a direct bond or a group selected from $-CONR^{14}-$, $-NR^{14}CO-$, $-O-$, $-COO-$, $-OCO-$, $-NR^{14}OCO-$, $-OCONR^{14}-$, $-NR^{14}CONR^{15}-$, $-S-$, $-SO-$, $-SO_2-$, $-COS-$ and $-SCO-$; and G^2 is a group selected from aryl, heteroaryl or heterocyclyl; wherein the alkyl groups and the group G^2 are optionally substituted by one or more substituents selected from group consisting of halogen atoms and alkyl, alkoxyalkyl, arylalkyl, $R^{16}OCO-$, hydroxy, alkoxy, oxo, $R^{16}R^{17}NCO-$, $-CN$, $-CF_3$, $-NR^{16}R^{17}$, $-SR^{16}$ and $-SO_2NH_2$ groups; wherein R^{10} to R^{17} are independently selected from hydrogen atoms and C_{1-4} alkyl groups; in the manufacture of a medicament for the treatment or prevention of a pathological condition or disease susceptible to amelioration by inhibition of phosphodiesterase 4.